On December 1, 2025 Mitsubishi Tanabe Pharma America, Inc. (MTPA) reported the change of its corporate name to Tanabe Pharma America, Inc. (TPA), effective immediately.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In July, MTPA’s parent company, Mitsubishi Tanabe Pharma Corporation (MTPC), announced it would undergo a corporate name change to Tanabe Pharma Corporation, effective December 1, 2025, following acquisition by Bain Capital, a leading global private investment firm. The new company name, "Tanabe Pharma," reflects the steadfast commitment to further global growth as an R&D-driven pharmaceutical innovator, while honoring the legacy of the former Tanabe Seiyaku, one of the world’s oldest pharmaceutical companies.

Though taking on a new name, TPA’s core values hold strong as the company remains dedicated to advancing science and creating hope for all underserved patient populations with complex needs.

"We have never stopped pursuing the impossible, as evidenced by our track record of discovering, researching, and developing a treatment for people living with ALS," said Yasutoshi Kawakami, President, Tanabe Pharma America. "We’re motivated to continue building on this legacy as we seek to discover innovative therapies to address the unmet needs of people living with debilitating diseases."

TPA will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions.

(Press release, Mitsubishi Tanabe Pharma, DEC 1, 2025, View Source [SID1234670245])